Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., today announced that the National Medical Products Administration (NMPA) of China has approved RYALTRIS Compound Nasal Spray (GSP 301 NS) for the treatment of Allergic Rhinitis (AR) in adults and children.

The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline and reflects continued progress in advancing innovative and differentiated therapies for patients with chronic conditions.

RYALTRIS is a first-of-its-kind fixed-dose combination nasal spray that brings together an olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid) to treat the symptoms of allergic rhinitis.

It is Glenmark’s first globally commercialized branded specialty product and is already approved in the United States, European Union, United Kingdom, Australia, South Korea, and Russia. Commercialization in China will be undertaken by Grand Pharmaceuticals Group Limited under an exclusive licensing agreement.

Commenting on the collaboration, Christoph Stoller, President and Business Head, Europe and Emerging Markets, Glenmark Pharmaceuticals Ltd., said, “The approval of RYALTRIS in China is a significant step in expanding our specialty respiratory portfolio. China is a priority market for Glenmark, and together with Grand Pharmaceuticals, our focus is on enabling access to this treatment for patients and healthcare professionals.”